Overview
Optibrium provides AI-driven software platforms like StarDrop for small molecule drug design, optimization, and data analysis in pharmaceutical R&D. Their tools, including Cerella for AI predictions, Semeta for metabolism forecasting, and BioPharmics for ligand- and structure-based design, enhance hit-to-candidate progression. These solutions integrate quantum mechanics, machine learning, and data visualization to improve compound prioritization and metabolic stability predictions.
Frequently asked questions
- What are Optibrium's key drug discovery platforms?
- StarDrop offers molecular design, optimization, and data analysis; Cerella provides AI-driven predictions from discovery data; Semeta predicts Phase I and II metabolism; BioPharmics enables ligand- and structure-based design.
- What capabilities does StarDrop's Metabolism module offer?
- It combines quantum mechanics and machine learning to predict metabolic fate across CYPs, AOXs, FMOs, UGTs, and SULTs, covering 80% of Phase I and 60% of Phase II human metabolism with regioselectivity and metabolite identification.
- Does Optibrium software integrate with other tools?
- StarDrop integrates with various drug discovery software for seamless data flow; Cerella connects securely to project data without compromising security.